HeimFTRE • NASDAQ
add
Fortrea Holdings Inc
19,73 $
Eftir lokun(0,00%)0,00
19,73 $
Lokað: 22. nóv., 16:16:10 GMT-5 · USD · NASDAQ · Lagalegir fyrirvarar
Við síðustu lokun
19,50 $
Dagbil
19,18 $ - 20,14 $
Árabil
16,53 $ - 41,02 $
Markaðsvirði
1,77 ma. USD
Meðalmagn
1,32 m.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(USD) | sep. 2024info | Breyting á/á |
---|---|---|
Tekjur | 674,90 m. | -5,45% |
Rekstrarkostnaður | 157,50 m. | 21,53% |
Nettótekjur | -27,90 m. | -99,29% |
Hagnaðarhlutfall | -4,13 | -110,71% |
Hagnaður á hvern hlut | 0,23 | -4,17% |
EBITDA | 12,00 m. | -72,22% |
Virkt skatthlutfall | 48,32% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
(USD) | sep. 2024info | Breyting á/á |
---|---|---|
Reiðufé og skammtímafjárfestingar | 105,30 m. | -4,01% |
Heildareignir | 3,66 ma. | -15,13% |
Heildarskuldir | 2,15 ma. | -18,01% |
Eigið fé alls | 1,51 ma. | — |
Útistandandi hlutabréf | 89,70 m. | — |
Eiginfjárgengi | 1,16 | — |
Arðsemi eigna | -0,64% | — |
Ávöxtun eigin fjár | -0,85% | — |
Peningaflæði
Breyting á handbæru fé
(USD) | sep. 2024info | Breyting á/á |
---|---|---|
Nettótekjur | -27,90 m. | -99,29% |
Handbært fé frá rekstri | -2,40 m. | -226,32% |
Reiðufé frá fjárfestingum | -8,10 m. | -400,00% |
Reiðufé frá fjármögnun | -14,00 m. | -81,82% |
Breyting á handbæru fé | -20,90 m. | -309,80% |
Frjálst peningaflæði | -19,35 m. | -269,37% |
Um
Fortrea Holdings Inc. is a contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates. Wikipedia
Framkvæmdastjóri
Stofnsett
apr. 1996
Vefsvæði
Starfsfólk
15.500